Mostrar el registro sencillo del ítem

Artículo

dc.creatorOlveira, Antonioes
dc.creatorAugustin, Salvadores
dc.creatorBenlloch, Salvadores
dc.creatorAmpuero Herrojo, Javieres
dc.creatorSuárez-Pérez, Jorge Alonsoes
dc.creatorArmesto, Susanaes
dc.creatorCarrascosa, José Manueles
dc.date.accessioned2024-02-09T14:14:03Z
dc.date.available2024-02-09T14:14:03Z
dc.date.issued2023
dc.identifier.citationOlveira, A., Augustin, S., Benlloch, S., Ampuero Herrojo, J., Suárez-Pérez, J.A., Armesto, S. y Carrascosa, J.M. (2023). The essential role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver disease. Life, 13 (2), 419. https://doi.org/10.3390/life13020419.
dc.identifier.issn2075-1729es
dc.identifier.urihttps://hdl.handle.net/11441/155068
dc.description.abstractInterleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and Tγδ cells) also contribute to the production of IL-17. In hepatocytes, IL-17 mediates systemic inflammation and the recruitment of inflammatory cells to the liver, and it is also implicated in the development of fibrosis and insulin resistance. IL-17 levels have been correlated with progression from MAFLD to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Clinical trials have shown that inhibiting IL-17A in patients with psoriasis could potentially contribute to the improvement of metabolic and liver parameters. A better understanding of the key factors involved in the pathogenesis of these chronic inflammatory processes could potentially lead to more efficient treatment for both psoriasis and MAFLD, and help to develop holistic strategies to improve the management of these patients.es
dc.formatapplication/pdfes
dc.format.extent13 p.es
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofLife, 13 (2), 419.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPsoriasises
dc.subjectMetabolic-associated fatty liver diseasees
dc.subjectMAFLDes
dc.subjectIL-17es
dc.subjectIL-17Aes
dc.titleThe essential role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver diseasees
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS)es
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.mdpi.com/2075-1729/13/2/419es
dc.identifier.doi10.3390/life13020419es
dc.journaltitleLifees
dc.publication.volumen13es
dc.publication.issue2es
dc.publication.initialPage419es

FicherosTamañoFormatoVerDescripción
The essential...pdf1.181MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional